| Dr Audrey O'connor, DO | |
|
1215 E Michigan Ave, Lansing, MI 48912-1811 | |
| (517) 364-1000 | |
| Not Available |
| Full Name | Dr Audrey O'connor |
|---|---|
| Gender | Female |
| Speciality | Hospice/palliative Care |
| Experience | 7 Years |
| Location | 1215 E Michigan Ave, Lansing, Michigan |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063932440 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 5101023380 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Legacy Emanuel Medical Center | Portland, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Legacy Clinics Llc | 0244144004 | 603 |
| Legacy Salmon Creek Hospital | 0446295711 | 223 |
News Archive
Today, BioMed Central announced a fund to help researchers in developing countries attend the conference, Parasite to Prevention. The conference, held in conjunction with Malaria Journal, takes place in Edinburgh UK, 20-22 October 2010.
Electrophysiologists Robert Stevenson, MD, and Jeffrey L. Williams, MD, MS, FACC, are safely implanting cardiac resynchronization therapy defibrillators in the Good Samaritan Hospital (GSH) Cardiology (Heart Failure) Program.
Melbourne scientists are a step closer to creating a new drug to stop a heart attack in its tracks and reduce the damage caused, without any side effects.
EpiCept Corporation today announced that the National Cancer Institute (NCI) has initiated a Phase II trial with crolibulinTM (EPC2407). The trial will assess the drug's efficacy and safety in combination with cisplatin in patients with anaplastic thyroid cancer (ATC). CrolibulinTM is a vascular disruption and apoptosis inducing agent that has demonstrated potent anti-tumor activity in both preclinical and early clinical studies.
› Verified 2 days ago
| Entity Name | Legacy Clinics Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902827272 PECOS PAC ID: 0244144004 Enrollment ID: O20031117000089 |
News Archive
Today, BioMed Central announced a fund to help researchers in developing countries attend the conference, Parasite to Prevention. The conference, held in conjunction with Malaria Journal, takes place in Edinburgh UK, 20-22 October 2010.
Electrophysiologists Robert Stevenson, MD, and Jeffrey L. Williams, MD, MS, FACC, are safely implanting cardiac resynchronization therapy defibrillators in the Good Samaritan Hospital (GSH) Cardiology (Heart Failure) Program.
Melbourne scientists are a step closer to creating a new drug to stop a heart attack in its tracks and reduce the damage caused, without any side effects.
EpiCept Corporation today announced that the National Cancer Institute (NCI) has initiated a Phase II trial with crolibulinTM (EPC2407). The trial will assess the drug's efficacy and safety in combination with cisplatin in patients with anaplastic thyroid cancer (ATC). CrolibulinTM is a vascular disruption and apoptosis inducing agent that has demonstrated potent anti-tumor activity in both preclinical and early clinical studies.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Audrey O'connor, DO 134 N Hayford Ave, Lansing, MI 48912-4143 Ph: () - | Dr Audrey O'connor, DO 1215 E Michigan Ave, Lansing, MI 48912-1811 Ph: (517) 364-1000 |
News Archive
Today, BioMed Central announced a fund to help researchers in developing countries attend the conference, Parasite to Prevention. The conference, held in conjunction with Malaria Journal, takes place in Edinburgh UK, 20-22 October 2010.
Electrophysiologists Robert Stevenson, MD, and Jeffrey L. Williams, MD, MS, FACC, are safely implanting cardiac resynchronization therapy defibrillators in the Good Samaritan Hospital (GSH) Cardiology (Heart Failure) Program.
Melbourne scientists are a step closer to creating a new drug to stop a heart attack in its tracks and reduce the damage caused, without any side effects.
EpiCept Corporation today announced that the National Cancer Institute (NCI) has initiated a Phase II trial with crolibulinTM (EPC2407). The trial will assess the drug's efficacy and safety in combination with cisplatin in patients with anaplastic thyroid cancer (ATC). CrolibulinTM is a vascular disruption and apoptosis inducing agent that has demonstrated potent anti-tumor activity in both preclinical and early clinical studies.
› Verified 2 days ago
Aline De Quadros Teixeira, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1200 E Michigan Ave Ste 500, Lansing, MI 48912 Phone: 517-364-5184 | |
Dr. Harry James Mccoy, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1540 Lake Lansing Rd, Ste 201, Lansing, MI 48912 Phone: 517-913-3900 Fax: 517-913-3901 | |
Ali H. Sheikh, D.O Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1140 E Michigan Ave Ste 400, Lansing, MI 48912 Phone: 517-364-9650 Fax: 517-364-9605 | |
Georgette Nader, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1215 E Michigan Ave, Lansing, MI 48912 Phone: 517-253-8366 | |
Salma Mohamed, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1215 E Michigan Ave, Lansing, MI 48912 Phone: 517-364-1000 | |
Dr. Cynthia S. Boynton, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1540 Lake Lansing Rd, Ste 201, Lansing, MI 48912 Phone: 517-913-3900 Fax: 517-913-3901 | |
Fadi Mohammadsaeed S Alreefi, M.D Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1140 E Michigan Ave Ste 400, Lansing, MI 48912 Phone: 419-921-2531 Fax: 517-364-9605 |